ADC Therapeutics CMO granted 213,900 RSUs

Zaki Mohamed reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Zaki Mohamed reported acquisition or exercise transactions in this Form 4 filing.

ADC Therapeutics SA Chief Medical Officer Zaki Mohamed received an equity award in the form of restricted stock units. On June 30, 2026 he was granted 213,900 RSUs, each representing the right to receive one common share at no purchase price.

The RSUs will vest on the earlier of June 30, 2027 or a qualifying termination without cause or for good reason, provided he remains employed through the vesting date. Following this grant, Mohamed holds 896,317 common shares directly, highlighting that this is a compensation-related award rather than an open-market share purchase or sale.

Insider Trade Summary

Grant/Award: 213,900 shares

Grant/Award 1 txn

Insider Zaki Mohamed

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	213,900	$0.00	$0.00

Holdings After Transaction: Common Shares — 896,317 shares (Direct)

Footnotes (1)

1. F1. Represents an award of restricted stock units ("RSUs") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Key Figures

RSU grant size: 213,900 RSUs Grant price per share: $0.00 per share Shares after transaction: 896,317 shares +2 more

5 metrics

RSU grant size 213,900 RSUs Award granted on June 30, 2026

Grant price per share $0.00 per share Compensation award, no purchase price

Shares after transaction 896,317 shares Total common shares held after RSU grant

RSU vesting date June 30, 2027 Time-based vesting, subject to continued employment

Employment-based vesting trigger Termination without cause/for good reason Alternative vesting trigger to June 30, 2027

Key Terms

restricted stock units, incentive award letter agreement, vest, contingent right

4 terms

restricted stock units financial

"Represents an award of restricted stock units ("RSUs") granted on June 30, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

incentive award letter agreement financial

"RSUs granted on June 30, 2026 pursuant to an incentive award letter agreement"

vest financial

"The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ADC Therapeutics (ADCT) disclose about Zaki Mohamed in this Form 4?

ADC Therapeutics reported that Chief Medical Officer Zaki Mohamed received a grant of 213,900 restricted stock units on June 30, 2026 as equity compensation, increasing his direct holdings to 896,317 common shares after the award.

How many shares are covered by the RSU grant to ADC Therapeutics CMO Zaki Mohamed?

The grant covers 213,900 restricted stock units for Zaki Mohamed. Each RSU represents a contingent right to receive one common share, providing potential future ownership if the vesting conditions tied to continued employment or qualifying termination are satisfied.

When do the RSUs granted to ADC Therapeutics CMO Zaki Mohamed vest?

The RSUs vest on the earlier of June 30, 2027 or his employment ending without cause or for good reason. Vesting is subject to his continued employment with ADC Therapeutics through the applicable vesting date specified in the award terms.

Did Zaki Mohamed buy or sell ADC Therapeutics (ADCT) shares in this Form 4?

No open-market buy or sell occurred in this Form 4. It reports a compensation-related acquisition: a grant of 213,900 restricted stock units at zero exercise price, rather than a cash purchase or sale in the market.

What is Zaki Mohamed’s total ADC Therapeutics shareholding after this RSU grant?

After the RSU award, Zaki Mohamed directly holds 896,317 common shares. This figure reflects his position following the grant reported on June 30, 2026, and helps show the overall scale of his equity stake.

Does the RSU grant to ADC Therapeutics CMO have performance conditions?

The RSUs vest based on time and employment status, not stated performance metrics. Vesting occurs on June 30, 2027 or upon certain qualifying terminations without cause or for good reason, assuming continued employment until that vesting event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 05:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zaki Mohamed

(Last) (First) (Middle)

430 MOUNTAIN AVENUE, SUITE 404

(Street)

NEW PROVIDENCE NEW JERSEY 07974

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ADC Therapeutics SA [ ADCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/30/2026		A	V	213,900(1)	A	$0	896,317	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units ("RSUs") granted on June 30, 2026 pursuant to an incentive award letter agreement. The RSUs will vest upon the earlier of (i) June 30, 2027 or (ii) termination of employment by the Issuer without cause or by the reporting person for good reason, subject to the reporting person's continued employment with the Issuer on the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Remarks:

	/s/ Lisa Kallebo, Attorney-in-Fact for Mohamed Zaki	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)